Targeting inflammation in coronary artery disease

New England Journal of Medicine

Volumn 377, Issue 12, 2017, Pages 1197-1198

  Harrington, Robert A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; METHOTREXATE; BIOLOGICAL MARKER;

CANCER RISK; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; EDITORIAL; HEART INFARCTION; HUMAN; INCIDENCE; INFECTION; INFLAMMATION; MORTALITY RISK; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

BIOMARKERS; CORONARY ARTERY DISEASE; CORONARY DISEASE; HUMANS; INFLAMMATION;

EID: 85029550224     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1709904     Document Type: Editorial

References (7)

1. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med 1999;340:115-26.
2. Alexander RW. Inflammation and coronary artery disease. N Engl J Med 1994;331:468-9.
3. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
4. Dhimolea E. Canakinumab. MAbs 2010;2:3-13.
5. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.
6. Canakinumab (Ilaris): common drug review. Ottawa: Canadian Agency for Drugs and Technologies in Health, November 2016 (https://www.ncbi.nlm.nih.gov/books/NBK409908/).
7. Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166(2):199-207.e15.